Acunivive 90 Injection System and Cubicin

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Ketorolac can affect kidney function and may increase the blood levels of DAPTOmycin when used together. Contact your doctor if you experience increased side effects or your condition changes. You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. You should seek immediate medical attention if you have unexplained muscle pain, tenderness or weakness, especially if accompanied by fever or dark colored urine, as these may be signs and symptoms of a serious medical condition known as rhabdomyolysis that can occasionally occur during treatment with DAPTOmycin. Rhabdomyolysis involves the breakdown of skeletal muscle tissue and, in some cases, can cause kidney damage and even death. Also let your doctor know if you experience other symptoms that could indicate more serious problems such as cough, breathlessness, fever, and burning, tingling, or numbness in the hands and feet. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

MONITOR: The concomitant administration of daptomycin and other nephrotoxic drugs or drugs that reduce renal filtration may result in additive renal effects and/or increased plasma levels of daptomycin. Daptomycin has been associated with renal impairment, although causality has not been determined. Increased plasma concentrations of daptomycin may increase the risk of myopathy. The risk may be increased in patients with pre-existing renal dysfunction.

MANAGEMENT: Serum drug concentrations and renal function, including serum creatinine, should be carefully monitored during concurrent administration. In addition, all patients receiving daptomycin should be monitored for the development of muscle pain or weakness, particularly of the distal extremities. CPK levels should be monitored weekly, and patients who develop unexplained elevations in CPK should be monitored more frequently. Daptomycin should be discontinued in patients with unexplained signs and symptoms of myopathy in conjunction with CPK levels exceeding 1000 U/L (approximately 5 times the upper limit of normal), or in patients without reported symptoms who have marked elevations in CPK (10 times the upper limit of normal, or more).

Acunivive 90 Injection System

Generic Name: ketorolac

Brand name: Sprix, Toradol

Synonyms: Ketorolac (nasal), Ketorolac (Nasal)

What is Acunivive 90 Injection System?

Cubicin

Generic Name: daptomycin

Brand name: Cubicin, Cubicin RF

Synonyms: n.a.

What is Cubicin?